NYSE:GMED - New York Stock Exchange, Inc. - US3795772082 - Common Stock - Currency: USD
79.25
-1.07 (-1.33%)
The current stock price of GMED is 79.25 USD. In the past month the price decreased by -14.53%. In the past year, price increased by 43.15%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 30.03 | 243.21B | ||
ISRG | INTUITIVE SURGICAL INC | 77.35 | 202.22B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.78 | 154.56B | ||
SYK | STRYKER CORP | 32.39 | 150.54B | ||
MDT | MEDTRONIC PLC | 17.66 | 120.92B | ||
BDX | BECTON DICKINSON AND CO | 16.42 | 65.60B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.25 | 42.11B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 19.25 | 39.50B | ||
IDXX | IDEXX LABORATORIES INC | 38.86 | 35.79B | ||
RMD | RESMED INC | 26.37 | 34.24B | ||
DXCM | DEXCOM INC | 52.12 | 33.59B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 18.18 | 24.78B |
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,000 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
GLOBUS MEDICAL INC - A
2560 General Armistead Ave
Audubon PENNSYLVANIA 19403 US
CEO: David M. Demski
Employees: 5000
Company Website: https://www.globusmedical.com/
Investor Relations: http://www.investors.globusmedical.com
Phone: 16109301800
The current stock price of GMED is 79.25 USD. The price decreased by -1.33% in the last trading session.
The exchange symbol of GLOBUS MEDICAL INC - A is GMED and it is listed on the New York Stock Exchange, Inc. exchange.
GMED stock is listed on the New York Stock Exchange, Inc. exchange.
22 analysts have analysed GMED and the average price target is 99.8 USD. This implies a price increase of 25.93% is expected in the next year compared to the current price of 79.25. Check the GLOBUS MEDICAL INC - A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GLOBUS MEDICAL INC - A (GMED) has a market capitalization of 10.79B USD. This makes GMED a Large Cap stock.
GLOBUS MEDICAL INC - A (GMED) currently has 5000 employees.
GLOBUS MEDICAL INC - A (GMED) has a support level at 79.24 and a resistance level at 80.32. Check the full technical report for a detailed analysis of GMED support and resistance levels.
The Revenue of GLOBUS MEDICAL INC - A (GMED) is expected to grow by 6.66% in the next year. Check the estimates tab for more information on the GMED EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GMED does not pay a dividend.
GLOBUS MEDICAL INC - A (GMED) will report earnings on 2025-05-05, after the market close.
The PE ratio for GLOBUS MEDICAL INC - A (GMED) is 25.24. This is based on the reported non-GAAP earnings per share of 3.14 and the current share price of 79.25 USD. Check the full fundamental report for a full analysis of the valuation metrics for GMED.
The outstanding short interest for GLOBUS MEDICAL INC - A (GMED) is 1.93% of its float. Check the ownership tab for more information on the GMED short interest.
ChartMill assigns a technical rating of 4 / 10 to GMED. When comparing the yearly performance of all stocks, GMED is one of the better performing stocks in the market, outperforming 89.28% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to GMED. Both the profitability and the financial health of GMED get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months GMED reported a non-GAAP Earnings per Share(EPS) of 3.14. The EPS increased by 34.76% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 4.09% | ||
ROA | 1.96% | ||
ROE | 2.47% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 79% to GMED. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 11.58% and a revenue growth 6.66% for GMED